Menu

Immunity May Make CRISPR-Based Therapies Ineffective

Researchers identify antibodies for two commonly used Cas9 proteins in human blood. Investors take notice.

Jan 10, 2018
Jim Daley

© BRYAN SATALINOCRISPR-Cas9 has been hailed as a breakthrough tool in genome editing that could usher in an era of precision gene therapy, and clinical trials are already scheduled to begin this year. But there may be a snag: our own immune systems.

The technique relies on Cas9 nucleases found in bacteria. But the majority of humans may have preexisting immune responses to bacteria from which the most common Cas9 homologs are derived, according to a preprint published last week (January 5) on bioRxiv.

The study, as MIT Technology Review first reported, examined the blood of 12 adults and 22 newborns for antibodies to Cas9 proteins from Staphylococcus aureus and Streptococcus pyogenes. They found antibodies for S. pyogenes in 65 percent of donors and antibodies for S. aureus in 75 percent—and nearly half of the donors had CD4+ T-cells that specifically targeted Cas9 homologs from S. aureus.

The immunity could not only limit the effectiveness of CRISPR, but also “create safety concerns,” the researchers write in the study. However, the problem is mostly limited to therapies that seek to edit genomes in vivo, they note—those that involve removing cells and editing genes in the lab may not be affected by this discovery.

“Like any new technology, you want to identify potential problems and engineer solutions for them,” study coauthor Matthew Porteus of Stanford University tells STAT News. “And I think that’s where we’re at. This is an issue that should be addressed.”

Executives at genome-editing companies, however, insist that the issues raised by this study “were either already being addressed or were not relevant to the medicines being developed,” according to STAT News

Shares of Intellia Therapeutics, Editas Medicine, and CRISPR Therapeutics were down the Monday after the paper was published, STAT News reports. 

September 2018

The Muscle Issue

The dynamic tissue reveals its secrets

Marketplace

Sponsored Product Updates

Enabling Genomics-Guided Precision Medicine

Enabling Genomics-Guided Precision Medicine

Download this eBook from Qiagen to learn more about the promise of precision medicine and how QCITM Interpret can help deliver better care with better knowledge.

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Download this white paper from Bertin Technologies to learn how to extract and analyze lipid samples from various models!

Bio-Rad Launches CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin for Process Protein Purification

Bio-Rad Launches CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin for Process Protein Purification

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of two new chromatography media for process protein purification: CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin.

Immunophenotypic Analysis of Human Blood Leukocyte Subsets

Immunophenotypic Analysis of Human Blood Leukocyte Subsets

Download this application note from ACEA Biosciences, Inc., to find out how to perform an immunophenotypic analysis of a human blood sample utilizing 13 fluorescent markers using a compact benchtop flow cytometer equipped with 3 lasers!